Abstract 1606P
Background
Sarcopenia refers to the loss of muscle mass and strength that occurs with aging and due to some medical conditions like cancer. Depression and inability to eat without assistance are common effects documented in cancer patients with sarcopenia. As a result, the goal of this study was to look into the relationship between sarcopenia, depression, and modes of feeding.
Methods
During the period beginning in January 2023 and ending in April 2023, cancer patients participated in a retrospective study. There has been a total of 150 participants enrolled in the trial, all of whom have been diagnosed with cancer. These people were enrolled in Mayo Hospital's Palliative Care Cancer Department in order to receive treatment. The Patient Health Questionnaire (PHQ-9) was used to determine the presence of depressive symptoms. The SARC-F was utilized to assess sarcopenia across all five dimensions. A self-report measure was utilized to assess modes of feeding [options include: 1) unable to eat without assistance 2) (self-fed with some difficulty, and 3) self-fed without any problem]. Sarcopenia, major depressive disorder, and feeding modes were studied using correlation analysis.
Results
We have observed a significant and negative association between modes of feeding and depression (r=-0.459, p<0.01), SARC1=Strength (r = -0.326, p<0.01), SARC2=Assistance in walking (r = -0.196, p<0.05), and SARC3=Rise from a chair (r = -0.238, p<0.01). These findings show that cancer patients are unable to eat without assistance when they suffer from sarcopenia which ultimately leads to more depressive symptoms.
Conclusions
Sarcopenia has a negative impact on the quality of life of patients, leading to depression and dependence on daily activities like self-eating which further complicates management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05